Apyx Medical (APYX) closed at $2.93 on November 6, 2026, down 4.2% from the previous close, on volume of 198,690 shares (30-day average 182,285).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Maxim Group Remains a Buy on Apyx Medical (APYX)
TipRanks (Fri, 6-Nov 4:15 PM ET)
H.C. Wainwright Sticks to Its Buy Rating for Apyx Medical (APYX)
TipRanks (Fri, 6-Nov 1:36 PM ET)
Apyx Medical’s Growth and Profitability Improve, but Price Target Remains Unchanged at $6
TipRanks (Fri, 6-Nov 9:02 AM ET)
Apyx Medical Earnings Call Highlights AYON Growth
TipRanks (Thu, 5-Nov 7:09 PM ET)
APYX pops as Surgical Aesthetics growth offsets OEM slump and EBITDA turns positive
Market Chameleon (Thu, 5-Nov 6:07 AM ET)
Apyx Medical beats top-line and bottom-line estimates; reaffirms FY26 outlook
Seeking Alpha News (Thu, 5-Nov 7:30 AM ET)
Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 4-Nov 6:00 PM ET)
Apyx Medical Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 4-Nov 11:32 AM ET)
PRNewswire (Thu, 22-Oct 10:00 AM ET)
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
Apyx Medical trades on the NASDAQ stock market under the symbol APYX.
As of November 6, 2026, APYX stock price declined to $2.93 with 198,690 million shares trading.
APYX has a beta of -0.54, meaning it tends to be less sensitive to market movements. APYX has a correlation of 0.01 to the broad based SPY ETF.
APYX has a market cap of $123.38 million. This is considered a Micro Cap stock.
Last quarter Apyx Medical reported $14 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $669,736 and exceeded earnings estimates by $.05.
In the last 3 years, APYX traded as high as $5.08 and as low as $.76.
The top ETF exchange traded funds that APYX belongs to (by Net Assets): VTI, VXF, IWC, BUSM, DFAC.
APYX has underperformed the market in the last year with a return of -12.5%, while the SPY ETF gained +10.8%. In the last 3 month period, APYX fell short of the market, returning -29.6%, while SPY returned -4.1%. However, in the most recent 2 weeks APYX has outperformed the stock market by returning +23.6%, while SPY returned -3.2%.
APYX support price is $2.90 and resistance is $3.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APYX shares will trade within this expected range on the day.